Miami Cancer Institute – Multispecialty Grand Rounds Evaluation - October 14, 2024

Please select one: *

I am in active clinical practice

I am retired

I am a student

Other

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Effectively identify patients with sarcoma who are candidates for immunotherapy and determine the most appropriate immunotherapy to improve their outcomes.	Effectively identify patients with sarcoma who are candidates for immunotherapy and determine the most appropriate immunotherapy to improve their outcomes. - 5	Effectively identify patients with sarcoma who are candidates for immunotherapy and determine the most appropriate immunotherapy to improve their outcomes. - 4	Effectively identify patients with sarcoma who are candidates for immunotherapy and determine the most appropriate immunotherapy to improve their outcomes. - 3	Effectively identify patients with sarcoma who are candidates for immunotherapy and determine the most appropriate immunotherapy to improve their outcomes. - 2	Effectively identify patients with sarcoma who are candidates for immunotherapy and determine the most appropriate immunotherapy to improve their outcomes. - 1
Identify new immunotherapy treatments being developed to further advance the medical management of cancer patients.	Identify new immunotherapy treatments being developed to further advance the medical management of cancer patients. - 5	Identify new immunotherapy treatments being developed to further advance the medical management of cancer patients. - 4	Identify new immunotherapy treatments being developed to further advance the medical management of cancer patients. - 3	Identify new immunotherapy treatments being developed to further advance the medical management of cancer patients. - 2	Identify new immunotherapy treatments being developed to further advance the medical management of cancer patients. - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? *

Please provide any additional comments or suggestions.

Name

You are here

Miami Cancer Institute – Multispecialty Grand Rounds Evaluation - October 14, 2024